| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,352 |
13,934 |
$810K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,648 |
1,646 |
$105K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,874 |
1,750 |
$103K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,382 |
1,380 |
$91K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,390 |
3,361 |
$82K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
7,104 |
6,781 |
$72K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,049 |
1,047 |
$61K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,625 |
1,488 |
$60K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
6,298 |
6,035 |
$57K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
833 |
721 |
$48K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
355 |
346 |
$29K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,811 |
1,733 |
$23K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
731 |
689 |
$22K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
391 |
378 |
$20K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
859 |
855 |
$14K |
| 99177 |
|
3,301 |
3,295 |
$10K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
278 |
253 |
$7K |
| 90461 |
|
454 |
454 |
$7K |
| 87634 |
|
108 |
104 |
$7K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
141 |
141 |
$5K |
| 0001A |
|
121 |
119 |
$5K |
| 85018 |
|
2,463 |
2,456 |
$5K |
| 0071A |
|
109 |
108 |
$5K |
| 0003A |
|
122 |
122 |
$5K |
| 0002A |
|
102 |
101 |
$5K |
| 0072A |
|
95 |
95 |
$4K |
| 90480 |
|
93 |
93 |
$3K |
| 96127 |
|
343 |
333 |
$3K |
| 90686 |
|
1,441 |
1,441 |
$2K |
| 91320 |
|
17 |
17 |
$2K |
| 0013A |
|
30 |
30 |
$1K |
| 81002 |
|
310 |
277 |
$908.93 |
| 99173 |
|
30 |
30 |
$675.63 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12 |
12 |
$423.96 |
| 90674 |
|
105 |
105 |
$418.40 |
| 92551 |
|
31 |
31 |
$307.83 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
17 |
13 |
$245.65 |
| 96160 |
|
112 |
109 |
$2.14 |
| 99072 |
|
448 |
400 |
$0.00 |
| 90685 |
|
30 |
30 |
$0.00 |
| 90633 |
|
28 |
28 |
$0.00 |
| 90670 |
|
121 |
121 |
$0.00 |
| 91300 |
|
364 |
341 |
$0.00 |
| 90672 |
|
15 |
15 |
$0.00 |
| 90734 |
|
27 |
27 |
$0.00 |
| 91307 |
|
185 |
163 |
$0.00 |
| 90619 |
|
85 |
81 |
$0.00 |
| 91301 |
|
78 |
77 |
$0.00 |
| 90677 |
|
147 |
142 |
$0.00 |
| 90651 |
|
125 |
125 |
$0.00 |
| 90680 |
|
59 |
59 |
$0.00 |
| 90697 |
|
62 |
62 |
$0.00 |
| 90698 |
|
25 |
25 |
$0.00 |
| 90620 |
|
99 |
99 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
16 |
12 |
$0.00 |
| 0012A |
|
20 |
20 |
$0.00 |
| 0011A |
|
22 |
22 |
$0.00 |